David Badesch MD
Critical Care Medicine, Pulmonary Vascular Medicine
Professor of Medicine, University Colorado
Join to view full profile
12605 E 16th Ave# F402Aurora, CO 80045
Phone+1 720-848-5300
Fax+1 720-848-0480
Dr. Badesch is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1987 - 1989- University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1987
Vanderbilt University Medical CenterResidency, Internal Medicine, 1983 - 1986
University of Virginia School of MedicineClass of 1983
Certifications & Licensure
CO State Medical License 1987 - 2027
TN State Medical License 1985 - 1995
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension Start of enrollment: 2006 Feb 01
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
- REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
Publications & Presentations
PubMed
- Survival Into Adulthood With FOXF1-Associated Pulmonary Vascular Disease After Neonatal Onset.Khalifah A Aldawsari, Steven H Abman, David Badesch, David Dunbar Ivy
Pulmonary Circulation. 2026-07-01 - Sotatercept Safety and Efficacy in Intermediate- to Low-Risk Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR.Mardi Gomberg-Maitland, H Ardeschir Ghofrani, J Simon R Gibbs, Marius M Hoeper, Marc Humbert
Chest. 2026-05-27 - 22 citationsSotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.Vallerie V McLaughlin, Marius M Hoeper, David B Badesch, H Ardeschir Ghofrani, J Simon R Gibbs
The New England Journal of Medicine. 2025-10-23
Press Mentions
How CU’s ‘Top Notch’ Training Helped a Pulmonologist Become a Hospital Chief and Global ResearcherMarch 10th, 2025- A Grateful Couple Supports CU Pulmonary Hypertension Research with Endowed ChairAugust 2nd, 2024
- Time from PAH Diagnosis Impacts Prognosis, Response to SelexipagAugust 5th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
